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THEROSCLEROSIS A is the most common cause of death in the Western world ac- 
counting for one half of all deaths.’ Hypercholes- 
terolemia, smoking, hypertension, diabetes mel- 
litus, obesity, and physical inactivity are 
identified as risk factors for this disease.2-h 
Control of all these factors is desirable, but 
cholesterol lowering has showed the greatest 
promise as regards reduction of cardiac events.’ 
Both primary and secondary intervention tri- 
als?-’ I have demonstrated that cardiac mortality 
decreases after lowering of plasma cholesterol 
levels, although total mortality was not impact- 
ed 17.1.3 
In animal models atherosclerotic lesions re- 
gress after a change in diet or the administra- 
tion of lipid-lowering drugs.14-l6 Calcium antag- 
onists have been reported to prevent the 
development of atherosclerosis in animal mod- 
els.” In these experiments lesions characterized 
by large amounts of intracellular lipids, in con- 
trast to the extracellular lipid accumulations 
characteristic of human atherosclerosis, were 
induced in a short time (3 to 24 months) by diets 
that resulted in excessively high plasma choles- 
terol levels (220 mmol/L).*6 Although these 
experiments have provided extensive insight 
into the pathological process, it is not justified 
to completely extrapolate these resuhs to hu- 
mans. 
To describe the effect of an intervention on 
the development of coronary artery disease 
(CAD) a trial with clinical end points only, 
acute myocardial infarction and cardiac death, 
is not sufficient. First, lesion growth is often 
asymptomatic.‘* Second, when progression of 
atherosclerosis is considered only if it has led to 
a cardiac event, one is not only monitoring slow 
progression but many other factors, such as 
plaque rupture, thrombosis, and vasospasm ca- 
pable of causing acute progression.1y-23 Third, in 
such a trial no distinction can be made between 
arrest, retardation of progression or regression 
of coronary atherosclerosis, and between dif- 
fuse and focal disease.‘” 
Many angiographic studies in men have been 
performed,‘5-41 of which some reported regres- 
sion of atherosclerosis in only a minority of 
patients, which could be explained by clot lysis 
in half of the cases.j6 However, these studies 
were often observational, retrospective. small, 
uncontrolled, and performed when quantitative 
coronary angiography was not available. 
Currently, the only method that can assess 
coronary or femoral atherosclerosis over time is 
repeated angiography.‘4 This article reviews the 
published controlled trials using serial coronary 
angiography with a lipid-modifying treatment, 
with calcium antagonists, and with lifestyle 
changes and the femoral atherosclerosis trials 
with lipid-modifying therapy. 
METHODS 
Selection 
Studies were considered if they fulfilled the 
following criteria: (1) the coronary or femoral 
artery anatomy was the object of the study, (2) 
repeated coronary or femoral angiography was 
used, (3) the study had an appropriate control 
group with which the treatment under study was 
compared, and (4) the lipid-modifying treat- 
ment resulted in a beneficial change of the lipid 
profile. In order to find trials that could fit these 
criteria, a computer-assisted literature search 
was performed, and references of papers were 
checked. The folIowing trials were selected. 
Coronary atherosclerosis with a lipid-modifying 
treatment: National Heart Long Blood Institute 
type II trial (NHLBI type II),“’ Cholesterol 
Lowering Atherosclerosis Study (CLAS),4” Pro- 
gram On the Surgical Control of the Hyperlipid- 
emias (POSCH), 14 Familial Atherosclerosis 
Treatment Study (FATS),4s Kane et akJh and 
the St Thomas’ Atherosclerosis Regression Study 
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(STARS)47; coronary atherosclerosis with a 
change in lifestyle: Lifestyle Heart Study4X.4y; 
coronary atherosclerosis with calcium anatago- 
nists: International Nifedipine Trial on Antiath- 
erosclerotic Therapy (INTACT),5U and Waters 
et a15i; femoral atherosclerosis with lipid- 
modifying therapy: Duffield et al,5’ Olsson et 
aL5” and CLAS.54 One study was rejected be- 
cause no substantial lipid-lowering effect was 
accomplished,55 and two studies were not in- 
cluded because the control group was not prop- 
erly selected. One study56 compared initial re- 
sponders with nonresponders to lipid lowering, 
another trials7 compared the lipid-modified 
group with a group of patients from another 
trial. Three studies were excluded because they 
did not give sufficient information to make a 
comparison possible.58-60 
Statistical Comiderations 
For each trial, relative risks with 95% confi- 
dence intervals for progression and regression 
of atherosclerosis were calculated.h1 The rela- 
tive risk is greater than one if the number of 
patients with progression or regression of CAD 
is increased in the index group. Because the 
definitions of change in coronary status differed 
between the trials, and no common angio- 
graphic end point could be defined, the defini- 
tions of progression and regression applied by 
the investigators of each individual study were 
used. For the FATS and the STARS studies, 
the two active treatment groups were combined. 
To obtain an overall measure of effect, the 
combined relative risks for progression and 
regression of atherosclerosis were calculated. 
The selected studies were pooled on the basis of 
common design characteristics, eg, coronary or 
femoral atherosclerosis, lipid-modifying ther- 
apy or treatment with calcium antagonists and 
not based on the result of a statistical test on 
heterogeneity of effect across the trials. The 
adjusted Mantel-Haenszel relative risk with 95% 
confidence interval was calculated.6’ To explore 
the relation between the magnitude of the 
lipid-regulating effect and the likelihood of 
progression or regression, linear regression anal- 
ysis was performed with each trial as a unit of 
analysis.“” The relative risks for progression and 
regression of CAD were taken as dependent 
variabIes. 
DESCRIPTION OF THE TRIALS 
Coronary Atherosclerosis Trials 
The design characteristics and the lipid and 
angiographic results of the selected trials are 
listed in Tables 1 through 5. Brensike et a14?JJ4 
treated patients with type 2 hyperlipoprotein- 
emia, low-density lipoprotein (LDL) in the 
upper 10th of the distribution of the general 
population, and proven CAD with diet alone 
(N = 72) or with diet and cholestyramine 
(N = 71) in a randomized double-blind man- 
ner. Coronary angiography was performed at 
baseline and after 5 years. Angiograms were 
assessed visually by a panel of experts. A de- 
crease of 16% in total cholesterol, 21% in LDL, 
and an increment of 6% in high-density lipopro- 
tein (HDL) were accomplished. Progression of 
CAD was noted in 49% of the placebo group 
and in 32% of the cholestyramine group. Regres- 
sion was found in 7% in each group. Twelve 
patients (17%) in the placebo group versus 8 
(11%) in the cholestyramine group died or 
suffered from an acute myocardial infarction 
(relative risk, 0.68; 95% confidence interval, 
0.30, 1.56). 
In the CLAS,4”J’5 nonsmoking, male patients 
with previous coronary bypass surgery and 
plasma cholesterol levels between 4.8 and 9.1 
mmol/L were treated with either diet alone 
(N = 94) or diet, colestipol, and nicotinic acid 
(N = 94). Patients were recruited by advertising 
in newspapers, on radio, and on television. 
Before randomization, all eligible patients were 
given the lipid-modifying drugs, and only those 
patients who had a reduction in total choles- 
terol of 2 15% entered the trial. The study was 
randomized and double-blind for treatment, 
plasma lipid values, and angiograms. Coronary 
angiograms were repeated after 2 years of 
treatment and were judged by a panel of cx- 
perts. Each patient was classified according to a 
global score of change, taking into account both 
the native coronary circulation and the bypass 
graftshh Total cholesterol decreased by 26%, 
LDL by 43%, and HDL increased by 37%. 
Progression of CAD was observed in 61% and 
regression in 2.4% of the placebo group; for the 
lipid-modified group, the figures were 39% and 
16%, respectively. Twenty-two patients in the 
placebo group and 21 (both 22%) in the lipid- 
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Table 1. Coronary Angiographic Atherosclerosis Trials 
Study Analysis Treatment Number 
Duration 
W Type of Patients 
Coronary atherosclerosis trials with lipid-modifying therapies 
NHLBI Type II Trial 
(1984) 
Visual panel R) placebo* 
I) cholestyramine” 
CLAS (1987) Visual panel 
POSCH (1990) Visual panel 
FATS (I 990) Quantitative and 
visual 
Kane et al (1990) Quantitative 
STARS (1992) Quantitative 
R) placebo* 82 
I) colestipol/niacin* 80 
R) usual care* 
I) partial ileal bypass 
surgery* 
R) conventional* 
I) lovastatin/colesti- 
po1* 
I) niacin/colestipol* 
R) placebo/resin* 
I) colestipol/niacin/ 
lovastatin* 
R) usual care 
I,) lipid-lowering diet 
12) diet/cholestyra- 
mine 
Coronary atherosclerosis trials with lifestyle changes 
Lifestyle Heart Trial Quantitative R) usual care 
(1990) I) lifestyle changes 
Coronary atherosclerosis trials with calcium antagonists 
INTACT (1990) Quantitative and R) placebo 
visual I) nifedipine 
Waters et al (1990) Quantitative and R) placebo 167 
visual I) nicardipine 168 
57 
59 
333 3 
363 (max 8) 
46 
38 
36 
2.5 
32 
40 
24 
26 
24 
19 
22 
175 
173 
5 
2 
Proven CAD, 82% 
NYHA I, type II hy- 
perlipoproteinemia, 
mean age 46 Years 
PostCABG. TC be- 
tween 4.8-9.1 
mmol.iL, mean age 
54 years 
Post MI, TC > 5.7 
mmol/L, mean age 
51 years 
Apolipoprotein 
B 2 125 mg/dL, 1 
lesion 2 50%. fam- 
ily history of CAD, 
67% angina, mean 
age 47 Years 
Familial hypercholes- 
terolemia: tendon 
xanthomas, LDL 2 
5.17 and TG 2 3.1 
mmol/L, mean age 
42 Years 
Proven CAD, TC be- 
tween 6.0-10.0 
mmol/L, mean age 
51 years 
Angiographically 
proven CAD, no 
lipid-modifying 
drugs, age 58 Years 
Mild CAD, 1 cardiac 
risk factor. 63% 
NYHP. I, mean age 
53 years 
5% to 75% stenoses 
in at least four seg- 
ments, 62% stable 
angina pectoris, 
mean age 51 Years 
Abbreviations: R, reference group; I, index group; TC, total cholesterol; TG, triglycerides; number, patients with angiographic 
follow-up. 
*Dietan/ counseling. 
modified group had a cardiac event. At the end Buchwald et a144,68,hy performed a large sur- 
of the study, patients who were willing to viva1 trial in patients after they had a first 
continue entered a 2-year extension of the trial myocardial infarction and who had total choles- 
which showed a sustained effect on lipids and terol levels of 2 5.7 mmol/L or 2 5.2 mmol/L in 
angiography at 4 years.67 Other end points of combination with a LDL level of 253.6 mmol/L 
the CLAS trial were the angiographically as- while on a diet. Patients were randomly allo- 
sessed change in femoral atherosclerosis and cated to diet and partial ileal bypass surgery’” 
the echo-Doppler evaluation of carotid athero- (N = 421) or diet only (N = 417). All analyses 
sclerotic disease. were reported on the basis of the intention-to- 
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Table 2. Definitions of Progression and Regression of CAD in Coronary Angiographic Atherosclerosis Trials 
Study Definition 
Coronary atherosclerosis trials with lipid-modifying theraptes 
NHLBI Type II Trial Definite progression: 2 1 lesion with definite progression and no lesion with regression 
Probable progression: 2 1 lesion with probable progression and no lesion with regression or deflmte 
progression 
Probable regression: 2 1 lesion with probable regression and no lesion with definite regression or any 
progression 
Definite regression: 2 1 lesion with definite regression and no progression 
Mixed response: regression and progression: lesion progression and regression in the same patient, 
whether definite or probable 
No change: no lesion observed as changed by at least two panels 
CLAS CLAS consensus global change score: 0, no change; 1, definitely discernable; 2, moderate; 3, extreme; 
-, regression; +. progression 
POSCH CLAS consensus global change score: 0, no change; 1, definitely discernable; 2, moderate; 3, extreme; 
-, regression; +, progression 
FATS Progression: 10% increase in percentage stenosis, regression vice versa 
Kane et al 10% increase in percentage stenosis, regression vice versa; change in % area stenosis 
STARS Progression: loss of ~0.17 mm in mean absolute width, regression gain ~0.17 mm 
Coronary atherosclerosis trials with lifestyle changes 
Lifestyle Heart Trial Change in % stenosis as a continuous measure: positive, progression; negative, regression 
Coronary atherosclerosis trials with calcium antagonists 
INTACT Progression: a decrease of > 0.4 mm in minimal lumen diameter, an increase in % stenosis > 20%; re- 
gression, vice versa 
Waters et al Progression: a decrease of >0.4 mm in minimal lumen diameter, an increase in % stenosis of > 10%; 
regression, vice versa 
treat principle. The mean duration of follow-up 
was 8.7 years. The main end point of the trial 
was total mortality. Apart from the clinical end 
points, sequential coronary angiography was 
performed at baseline and after 3, 5, 7, and 10 
years. Angiograms were assessed as in the 
CLAS triaLh” Total cholesterol and LDL de- 
creased 32% and 35%, respectively; HDL in- 
creased 6%. Total mortality was reduced by 
22% (95% confidence interval, 17%, 47%) and 
cardiovascular death combined with nonfatal 
acute myocardial infarction was reduced by 
Table 3. Lipid Results of Coronary Angiographic Atherosclerosis Trials With Lipid-Modifying Therapies 
Study 
Total Cholesterol LDL Cholesterol HDL Cholesterol Trlglycerldes 
Group I3 T  Cl%) El T  CWI B T  C(%J I3 T  c (%) 
Coronary atherosclerosis trials w/N, l/p/d-modifying therapies 
NHLBI Type II Trial PI 7.59 7.49 -1 5.93 
I 8.03 6.63 -17 6.27 
CLAS R 6.28 6.00 ~4 4.36 
I 6.35 4.65 -26 4.42 
POSCH R 6.48 6.14 -5 4.62 
I 6.50 4.71 -36 4.62 
FATS R 6.79 6.55 -4 4.53 
4 7.12 4.71 -34 5.08 
12 6.99 5.41 ~23 4.92 
Kane et al R 9.49 8.67 -8 7.11 
I 9.79 6.75 -31 7.32 
STARS R 7.07 6.93 -2 4.82 
1, 7.19 6.17 -14 5.00 
12 7.44 5.56 ~25 5.26 
Coronary atherosclerosis trials with lifestyle changes 
Lifestyle Heart Trial R 6.34 6.00 ~5 4.32 
I 5.88 4.45 ~24 3.92 
5.67 -5 1.01 1.01 2 1.48 1.86 26 
4.61 -26 0.98 1.06 a 1.76 2.25 28 
4.13 -5 1.13 1.15 2 1.74 1.59 5 
2.51 -43 1.15 1.57 37 1.71 1.25 --22 
4.30 -7 1.05 1.04 -1 2.26 2.17 -4 
2.68 ~42 1.03 1.08 5 2.33 2.60 12 
4.20 -7 0.98 1.04 6 2.59 298 15 
2.77 -- 45 0.91 1.06 16 2.27 2.07 --9 
3.34 -32 1.01 1.42 41 2.19 1 55 29 
6.27 -12 1.31 1.32 0 1.24 1.29 4 
4.45 -39 1.22 1.53 25 1.49 1.17 -21 
4.67 -3 1.22 1.21 -1 2.32 2.35 1 
4.19 -16 1.14 1.14 0 2.31 1.85 - 20 
3.37 -36 1.24 1.19 --4 2.20 2.21 0 
4.07 -6 1.35 1.31 -3 2.45 2.24 --9 
2.46 -37 1.00 0.97 ~3 2.38 2.91 22 
NOTE. All values are in mmol/L. 
Abbreviations: R, reference group; I, index group: 6, at baseline; T, during the trial; C, percentage change 
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Table 4. Angiographic Results of Coronary Atherosclerosis Trials: Progression of CAD 
Number of Patients Rate 
Study Group (ProgresslonlTotal) WI Relative Risk (95% CII 
Coronary atherosclerosis trials with lipid-modifying therapies 
NHLBI Type II Trial 
CLAS 
POSCH 
FATS 
Kane et al. 
STARS 
Overall result 
R 
I 
R 
I 
R 
I 
R 
h&2 
R 
I 
R 
I,&2 
28157 49 
19159 32 
49180 61 
32182 39 
138/333 41 
102/363 28 
21146 46 
17174 23 
13132 41 
8/40 20 
11124 46 
7150 14 
0.66 (0.42, 1.03) 
0.64 (0.46, 0.88) 
0.68 (0.55, 0.84) 
0.50 (0.30, 0.85) 
0.50 (0.23, 1.04) 
0.31 (0.14, 0.69) 
0.62 (0.54, 0.72) 
Coronary atherosclerosis trials with lifestyle changes 
Lifestyle Heart Trial R 
I 
10119 53 
4122 18 
0.35 (0.13,0.92) 
Coronary atherosclerosis trials with calcium antagonists 
INTACT (0.4 mm) R 
I 
Waters et al (0.4 mm) R 
I 
541175 31 
441173 25 
611167 37 
651168 39 
0.82 (0.59, 1.16) 
1.06 (0.80, 1.40) 
Overall result 0.95 (0.77, 1.18) 
Abbreviations: R, reference 9roup; I, index goup; 95% Cl, 95% confidence interval. 
Table 5. Angiographic Results of Coronary Atherosclerosis Trials: Regression of CAD 
Number of Patients 
Study Group (Regression/Total) 
Coronary atherosclerosis trials with lipid-modifying therapies 
Rate 
W) 
Relative Risk 
(95% Cl) 
NHLBI Type II Trial 
CLAS 
POSCH 
FATS 
Kane et al 
STARS 
Overall result 
R 
I 
R 
I 
R 
I 
R 
II&2 
R 
I 
R 
1% 
4157 
4159 
2180 
13180 
241333 
331363 
5146 
26174 
4132 
13140 
1124 
18150 
7.0 
6.8 
2.4 
16.2 
7.2 
9.1 
11 
35 
13 
33 
4.2 
36 
0.97 (0.25, 3.68) 
6.67 (1.55, 28.89) 
1.26 (0.76. 1.09) 
3.20 (1.34, 7.82) 
2.60 (0.94, 7.20) 
8.64 (1.22,61.0) 
2.13 (1.53, 2.98) 
Coronary atherosclerosis trials with lifestyle changes 
Lifestyle Heart Trial R 
I 
Coronary atherosclerosis trials with calcium antagonists 
INTACT (0.4 mm) R 
I 
Waters et al (0.4 mm) R 
I 
Overall result 
8119 42 
18122 82 
301175 17 
211173 12 
211167 13 
311168 19 
1.90 (1.11.3.41) 
0.71 (0.42, 1.19) 
1.47 (0 88, 2.45) 
1.02 (0.72, 1.46) 
Abbreviations: R, reference goup; I, index 9roup; 95% Cl, 95% confidence interval. 
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Table 6. Femoral Angiographic Atherosclerosis Trials 
Study AIl&SlS Treatment Number Duration Type of Patient 
Duffield et al (1983) Quantitative and visual R) placebo* 12 18 months Claudicatio intermittens 
I) diet, cholestyramine, 12 for z 6 months, TC t 
colestipol, nicotinic 6.5 mmolil and/or 
acid* TG z 1.8mmol/l, 
mean age 55 years 
Olsson et al ( 1990) Visual R) placebo; 20 18 months Hyperlipoproteinemia, no 
I) nicotinic acid, fenofi- 23 symptoms of cardlo- 
brate* vascular disease, 
TC 2 9.5 mmol/L an- 
d/or TG 2 3.5 mmol/L, 
mean age 52 years 
CLAS (1991) Quantitative and visual R) placebo* 76 2 years PostCABG, TC between 
I) colestipol-niacin* 77 4.8 and 9.1 mmol/L, 
mean age 54 years 
Abbreviations: R, reference group; I, index group: TC, total cholesterol; TG, triglycerides; number, patients with angiographic 
follow-up. 
*Dietary counseling. 
35% (95% confidence interval, 9%, 53%). Pro- 
gression of CAD measured after 3 years was 
found in 41% of the control group versus 28% 
of the operated group. Regression occurred in 
7% versus 9% of the patients. 
Brown et a14s.71 reported a randomized study 
in men with apolipoprotein B levels 2 125 
mg/dL, proven CAD, and a positive family 
history of vascular disease. Patients were treated 
with diet and placebo (N = 27) or colestipol 
(N = 20), lovastatin and colestipol (N = 38), 
and nicotinic-acid and coIestipo1 (N = 36). Pa- 
tients were followed for 2.5 years. The coronary 
angiograms were analyzed both visually and 
Table 7. Definitions of Progression and Regression in 
Femoral Angiographic Atherosclerosis Trials 
Study 
Duffield et al 
Olsson et al 
CLAS 
Definition 
Visual: change in plaque height 
Quantitative: a positive or negative 
change in the edge irregularity index 
A positive or negative change in per seg- 
ment score (0, no lesion; 1, single 
plaque < 50%; 2, more than 1 plaque 
< 50%; 3, single plaque > 50%; 4, 
more than one plaque > 50%) 
A positive or negative change in overall 
atherosclerosis score (the average 
segment score) 
Progression: progression in at least 1 
segment no change in others 
Regression: regression in at least 1 seg- 
ment no change in others 
No change: no change in all segments 
In cass of mixed response: the modal 
segmental response was taken 
quantitatively.7’ Total cholesterol was reduced 
by 30% and 19%, LDL by 38% and 25%. and 
HDL was increased by 20% and 35% for the 
colestipol/lovastatin and nicotinic-acid/colesti- 
pol groups respectively relative to the conven- 
tionally treated group. Angiographic progres- 
sion was noted in 46%, 21%, and 25%, and 
regression was noted in 1 l%, 32%, and 39% for 
the placebo/colestipol, colestipol/lovastatin, and 
the nicotinic-acid/colestipol groups, respec- 
tively. Less clinical events defined as death, 
acute myocardia1 infarction, or new refractory 
ischemia requiring revascularization were ob- 
served in the lipid-modified group: 10 (19%) 
versus 5 (5%) (relative risk, 0.28; 95% confi- 
dence interval, 0.10,0.77). 
In the trial performed by Kane et al,J” both 
males and females with heterozygous familial 
hypercholesterolemia, proven CAD, tendon xan- 
thomas, LDL cholesterol 2 5.2 mmol/L, triglyc- 
erides 2 3.1 mmol/L, or without tendon xantho- 
mas but with a first-degree relative with 
xanthomas and LDL 26.5 mmol/L were pro- 
vided with conservative treatment (N = 49) or a 
combination of LDL-lowering drugs (N = 48) 
in a randomized, unblinded fashion. Drugs used 
were colestipol, resin, nicotinic-acid, and lovas- 
tatin. Quantitative coronary analysis was per- 
formed at baseline and after 2 years.7’ Total 
cholesterol, LDL, and HDL were changed by 
-23%, -37%, and 25%, respectively. Progres- 
sion of CAD took place in 41% and 20% and 
regression in 13% and 33% of the placebo and 
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Table 8. Lipid Results of Femoral Angiographic Atherosclerosis Trials 
Total Cholesterol LDL Cholesterol HDL Cholesterol Triglycerides 
Study Group B T  c I”/.) B T  c (%) B T  c 1%) B T  c 1%) 
D&field et al R 7.72 7.48 3 5.19 5.13 -1 1.20 1.10 -a 3.10 2.87 -7 
I 8.05 6.06 -25 5.41 3.91 -28 1.23 1.55 26 3.25 1.80 -45 
Olsson et al R a.10 a.00 1 5.74 5.23 -9 1.29 1.33 3 2.67 2.53 -5 
I 9.86 6.37 -35 6.44 3.89 -40 1.47 1.81 23 2.86 1.16 -59 
CLAS R 6.25 5.99 -4 4.34 4.14 -5 1.13 1.13 0 1.74 1.61 -7 
I 6.32 4.62 -27 4.39 2.48 -44 1.13 1.55 37 1.73 1.26 -27 
NOTE. All values are in rnmol/L. 
Abbreviations: R. reference group; I, index group; B, at baseline; T, during the trial; C, percentage change. 
the lipid-modified groups, respectively. The 
mean change in percent area stenosis was 
-1.53% in the conventional and 0.80% in the 
lipid-modified group. After stratification for 
sex, the angiographic benefit expressed in per- 
cent area stenosis was statistically significant in 
females but not in males. Only 1 patient, a 
control group subject, had a cardiac event. 
STARS4’ tested a lipid-lowering diet alone 
and a diet in combination with cholestyramine 
to neither diet or medication. In the lipid- 
lowering diet, total fat intake was reduced to 
27% of dietary energy. Saturated fatty acid 
constituted 8% to 10% of dietary energy. Male 
patients with total cholesterol levels between 
6.0 and 10.0 mmol/L, without previous revascu- 
larization procedure, were enrolled in a short 
trial to test tolerability and responsiveness to 
cholestyramine. Quantitative coronary angiogra- 
phy was performed at baseline and after 3 
years.73 Ninety patients were recruited. Total 
cholesterol levels decreased by 12% and 23% 
and LDL by 13% and 33% in the diet and 
diet-cholestyramine groups, respectively. HDL 
remained at the same level in all treatment 
groups. Progression of CAD was found in 46% 
and 14% and regression in 4.2% and 36% of the 
usual care and the lipid-modified groups, respec- 
tively. The change in mean coronary diameter 
was 0.20 mm, 0.03 mm, and 0.10 mm in the usual 
care, the diet, and the diet-cholestyramine 
groups, respectively. Ten cardiac events (36%) 
took place in the usual care group versus four 
(8%) in the lipid-modified group (relative risk, 
0.21; 95% confidence interval, 0.07,0.61). 
The Lifestyle Heart Study48 investigated 
whether comprehensive lifestyle changes could 
influence CAD. Patients with proven CAD 
were randomly assigned to either a control 
group (N = 20) or to an experimental group 
(N = 28) that was exposed to a low-fat vegetar- 
ian diet, stress-management techniques, individ- 
ually prescribed exercise, and twice-weekly (4 
hours) group meetings for social support to 
adhere to the treatment program. Dietary en- 
ergy consisted of 10% of fat intake, of which less 
than 50% was unsaturated fat. No lipid- 
modifying drugs were allowed. Angiograms were 
assessed quantitatively74 at baseline and after 1 
year. As an indication of overall compliance to 
the proposed lifestyle changes, a total adher- 
ence score was defined. This score was one if 
the program was followed completely. For the 
control group the adherence was 0.56 and 0.62 
at baseline and after 1 year, respectively. For 
the experimental group these figures were 0.55 
and 1.22 indicating a more than sufficient com- 
pliance. Differences between the groups in total 
cholesterol, LDL, and HDLwere .- 19%, -31%, 
and O%, respectively. Both blood pressure and 
bodyweight decreased in the experimental group. 
The frequency of angina1 attacks decreased in 
the experimental group (-90%) and increased 
in the control group (160%). Progression and 
regression of CAD were observed in 53% and 
42% and in 18% and 82% in the usual care and 
Table 9. Angiographic Results of Femoral Atherosclerosis 
Trials: Progression of CAD 
Number of 
Patients Ras? Relative Risk 
Study Group (Progression/Total) I%) (95% Cl) 
Duffield et al R 271156 17 0.40 (0.20, 0.80) 
I 10/144 7 
Olsson et al R 10125 40 0.59 (0.22, 1.57) 
I 4117 24 
CLAS R 30/76 40 0.70 (0.44, 1.09) 
I 21177 27 
Overall result 0.67 (0.44,1.01) 
Abbreviations: R, reference group; I, index group; 95% Cl, 
95% confidence interval. 
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Table 10. Angiographic Results of Femoral Atherosclerosis Trials: Regression of CAD 
Study Group 
Number of Patients 
(Regression/Total) 
Rate 
i%) Relative Risk (95% Cl) 
Duffield et al 
Olsson et al 
CLAS 
Overall result 
R 7146 15 
I 15146 33 
R 0125 0 
I 15127 56 
R 21176 28 
I 35177 52 
2.14 (0.96, 4.76) 
-56%* (- 74%. -37%) 
1.89 (1.23, 2.91) 
1.93 (1.27, 2.92) 
Abbreviations: R, reference 9roup; I, index group; 95% Cl, 95% confidence interval. 
*Risk difference. 
the lifestyle changes groups, respectively. An 
additional analysis49 of the coronary angiograms 
also showed a beneficial effect of the lifestyle 
changes on stenosis geometry, which resulted in 
an increase in the theoretical stenosis flow 
reserve.75 
Lichtlen et a15” reported INTACT in which 
the antiatherosclerotic properties of the cal- 
cium antagonist nifedipine were determined. 
Patients with proven mild CAD and at least one 
risk factor were randomized to placebo 
(N = 211) or nifedipine 80 mg/d (N = 214). 
Quantitative coronary angiography was per- 
formed at baseline and after 3 years.“j Progres- 
sion occurred in 31% and 25% and regression in 
17% and 12% in the placebo and nifedipine 
groups, respectively. INTACT showed a reduc- 
tion in the development of new lesions, defined 
as new stenosis of 2 20% (103 versus 144). This 
was independent of the effect of nifedipine on 
blood pressure. More patients died in the nife- 
dipine group (12 versus 2) and the cardiac 
mortality rate was 2.4% and 0.8% per year. 
Waters et a151,77 studied the effect of the 
calcium antagonist nicardipine on CAD. Pa- 
tients with an 80% probability of coronary 
atherosclerosis progression according to the 
extent of CAD related to age78 were randomly 
allocated in a double-blind fashion to placebo 
(N = 191) or nicardipine 120 mg/d (N = 192). 
Angiograms were repeated after 2 years and 
analyzed quantitatively.76 Progression and re- 
gression of CAD were observed in 37% and 
13% and in 39% and 19% in the placebo and 
the nicardipine groups, respectively. 
Femoral Atherosclerosis Trials 
The design characteristics and lipid and angi- 
ographic results are shown in Tables 6 through 
10. Duffield et a152,75) performed a randomized 
double-blind controlled trial in patients with 
symptomatic peripheral atherosclerosis. Pa- 
tients were provided either usual care (N = 12) 
or lipid-modifying drugs (N = 12). Femoral an- 
giography was performed at baseline and after 
19 months. Total cholesterol was reduced 28% 
LDL reduced 31%, and HDL increased by 34%. 
Angiography was analyzed visually and quantita- 
tively and reported on a segmental basis. Pro- 
gression was observed in 17% and 7% and 
regression in 15% and 33% in the placebo and 
the lipid-modified groups, respectively. 
In the trial conducted by Olsson et al,‘j 
asymptomatic hyperlipidemic middle-aged men 
were treated with nicotinic-acid, fenofibrate 
(N = 23) or received dietary advice (N = 20). 
Angiography was assessed visually at baseline 
and after 1 year. Total cholesterol decreased 
34%, LDL decreased 31%. and HDL increased 
19%. Progression and regression were observed 
in 40% and 0% in the conservatively treated 
group and in 24% and 29% of the lipid-modified 
group. 
As mentioned previously, CLASS4 also stud- 
ied the development of femoral atherosclerosis. 
Design and treatment are described earlier. 
The assessment of femoral atherosclerosis was 
performed quantitatively.65 Progression of fem- 
oral atherosclerosis occurred in 40% versus 
27%, and regression occurred in 28% and 52% 
of the placebo- and lipid-modified groups, re- 
spectively. 
Relation Between Angiographic Changes Lipid 
and Nonlipid Factors 
In the NHLBI type II study,8(’ a decrease in 
LDL, in total cholesterol, and an increase in 
HDL were all associated with a lower rate of 
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CAD progression, although the first two factors 
were not independent. A decrease in LDL and 
an increase in HDL, expressed in the HDL/ 
LDL ratio, was related to less progression of 
CAD. No relation was found between the abso- 
lute values of total cholesterol, LDL, and HDL 
and the changes in CAD. Blankenhorn et alx’ 
found in univariate analysis that total choles- 
terol, LDL, HDL, nonHDL cholesterol (LDL 
and VLDL), apolipoprotein B and C, triglycer- 
ides, and diastolic blood pressure were related 
to progression of CAD. After multivariate anal- 
ysis, only nonHDL cholesterol in the placebo 
group and apolipoprotein C (measured in whole 
serum) in the lipid-modified group were found 
to be independent determinants of the global 
change score. In a study on the development of 
new angiographic lesions in the placebo group,82 
Blankenhorn found that high age at entry and a 
decrease in systolic blood pressure during the 
trial were associated with a lower incidence of 
new lesions. Brown et a145 found that the change 
in proximal stenoses was determined by the 
change in apolipoprotein B or LDL, in HDL, in 
systolic blood pressure, and the amount of ST 
segment depression at the baseline exercise 
test. Kane et a14h could best predict the change 
in mean percent area stenosis by the LDL level 
during the trial. In the STARS tria14’ the change 
in mean coronary diameter related most strongly 
to the change in mean blood pressure and the 
LDLiHDL ratio during the trial. Regression of 
CAD was strongly related to a LDL level of 
< 3.5 mmol/L. 
Progression 
POSCH 
CLAS 
Fig 1. Relative risksforangio- 
graphic progression and regres- 
sion of CADfor each lipid-modify- 
ing trial and the overall relative 
risk. The horizontal bars indicate 
the 95% confidence interval. For 
FATS 
NHLBI II 
STARS 
._ 
Pooled Remits 
For the combined coronary atherosclerosis 
trials with lipid-modifying regimes, the overall 
relative risk (ORR) for progression was 0.62 
(95% confidence interval, 0..54,0.72) corre- 
sponding with a reduction of 36”/0. The ORR 
for regression was 2.13 (95% confidence inter- 
val, 1.53, 2.98) (Fig 1). For the two studies using 
a calcium antagonist, the ORR for progression 
was 0.95 (95% confidence interval, 0.77, 1.18) 
and for regression 1.02 (95% confidence inter- 
val, 0.72, 1.46) (Fig 2). Of the three studies on 
femoral atherosclerosis, only two were pooled 
since the trial of Duffield et al was reported on a 
segmental and not on a per patient basis. The 
ORRs were 0.67 (95% confidence interval, 
0.44, 1.01) and 1.93 (95% confidence interval, 
1.27 = 2.92) for progression and regression, 
respectively. 
Figure 3 shows the relation between the 
change in HDL/LDL ratio and relative risk for 
progression and regression of CAD among the 
different trials. No association could be found 
between these variables and changes in CAD. 
Results of Other Angiographic Studies 
Table 11 depicts the angiographic results of 
studies that were not selected. Progression of 
CAD occurred in approximately 40% to 80% of 
the patients. Regression of CAD was found in 
some of the observational trials but in no more 
than 8% of the cases. 
Regression 
POSCH 
CLAS 
- FATS 
progression the portion left to 
the line of unity indicates a bene- 
ficial effect (reduction in progres- 
Kane er al. 
Overall 95% Cl: 0.54 0.72 
sion); for regression the portion 
right to the line of unity indicates r I-- 
a beneficial effect (increase in 0 0.6 1 I.6 2 2.6 3 0 1 2 3 4 6 6 7 6 6 10 11 12 13 14 16 
regression). Relative Risk with 95% Cl Relative Risk with 95% Cl 
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Progression 
--I 
INTACT 
A- Waters et al. 
Overall 95% Cl: 0.77 1.19 
0 0.6 1 1.6 2 2.6 3 0 
Ftelativs Risk with 95% Cl 
Regression 
1 
INTACT 
Waters et al. 
1 Overall 95% Cl: 0.71 1.47 
i 
0.6 1 1.6 2 2.6 3 
Relative Risk with 95% Cl 
DISCUSSION 
Angiographic Trials 
The use of coronary angiography as end point 
for a trial is attractive. First, it is the only 
method that can actually document slowing, 
arrest, or regression of CAD.‘4 Second, a trial 
using angiography needs less patients than one 
with clinical end points to yield sufficient statis- 
tical power.R3-R6 Third, the completion time of 
the study can be shorter, especially in the case 
of CAD with a low clinical event rate.x6,87 
Fourth, accurate and precise measuring meth- 
ods can be applied.7h.84 
Nevertheless, coronary angiography also has 
its drawbacks. First, no data are available on 
patients without an indication for coronary 
angiography. Second, the assessment of the end 
point is not continuous as with survival analysis 
but in most cases only at two moments in time. 
Fig 3. Scatter plot of the dif- 
ference in change in the HDLI 
LDL ratio between the placebo 
and lipid-modified group and the 
relative risk for progression and 
regression of CAD. Linear regres- 
sion analysis did not show a rela- 
tion between lipid-modifying and 
angiographic effect among the 
trials. 
POSCH 
NHLBI Ii . 
Fig 2. Relative risks for angio- 
graphic progression and regres- 
sion of CAD for both calcium 
antagonist trials and the overall 
relative risk. The horizontal bars 
indicate the 95% confidence 
interval. For progression the 
portion left to the line of unity 
indicates a beneficial effect (re- 
duction in progression); for re- 
gression the portion right to the 
line of unity indicates a beneficial 
effect (increase in regression). 
Third, coronary angiography is an invasive pro- 
cedure not without risks to the patient.x8 Fourth, 
angiographic follow-up will never be available 
for all enrolled patients. Reasons for lack of 
angiographic follow-up can be independent, eg, 
a move or refusal for a second angiogram, but 
also dependent of the patient’s clinical status, 
eg, death, acute myocardial infarction, or other 
illness. In the latter case this can result in an 
underestimation of the rate of progression in an 
observational study. Also, in a clinical trial 
when a new therapy is effective, underestima- 
tion of the treatment effect can occur because 
more failures in the reference group than in the 
index group cannot be included in the compari- 
son. In such a case, the angiographic difference 
will be smaller than the true difference between 
treatments. 
Angiographic trials are a logical step in the 
*- 
8 j 
STARS 
7i CLAS 
CIAS 
:I 
FATS I 
FATS 
POSCH 
NHLBI II 
100 125 160 7.6 50 76 100 126 so 
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Table 11. Angiographic Results of Rejected, Single-Group, and Observational Studies 
Number of Patients 
445 
Study 
Cohn et al (1975) 
Nash et al (1982) 
Nikkill et al (1984) 
Loaldi et al (1989) 
Hahmann et al (1991) 
Schuler et al (1992) 
Kuo et al (1979) 
Arntzenius et al (1985) 
Gensini et al (1972) 
Bemis et al (1973) 
Nash et al (1977) 
Marchandise et al (1978) 
Bruschke et al (1981) 
Kramer et al (1982) 
Moise et al (1984) 
Bruschke et al (1988) 
&t et al (1967) 
Barndt et al (1977) 
Total wo) 
24 
16 
17 
25 
13 
28 
38 
38 
39 
21 
21 
18 
18 
25 
39 
1,263 
73 
119 
22 
26 
256 
317 
313 
168 
28 
25 
Progression No Change 
WI 
- 
15 (69) 
11 (63) 
8 (47) 
3 (12) 
12 (92) 
19 (68) 
18 (47) 
19 (53) 
12 (31) 
21 (100) 
10 (45) 
6 (33) 
5 (28) 
4 (16) 
21 (54) 
985 (78) 
38 (52) 
106 (89) 
cl i-j 
7 (26) 
144 (56) 
148 (47) 
139 (44) 
66 (39) 
1 (4) 
13 (52) 
9 (31) 
5 137) 
9 (53) 
22 (88) 
1 (8) 
9 (321 
17 (45) 
14 (39) 
20 (51) 
0 (4 
0 i-1 
11 (61) 
6 (33) 
21 (84) 
18 (46) 
276 (22) 
35 (48) 
13 (11) 
22 (100) 
19 (74) 
100 (39) 
154 (49) 
162 (52) 
88 (52) 
8 (29) 
3 (12) 
Regression 
W 
Duration 
kfr) Type - 
0 i-1 
0 i-1 
0 t-1 
0 i-1 
0 i-j 
0 i-1 
3 (8) 
3 (8) 
7 (18) 
0 i-j 
11 (55) 
1 (6) 
7 cw 
0 (6) 
0 i-) 
2 (0.2) 
0 i-) 
0 i-j 
0 I-1 
0 i-) 
12 (5) 
15 (5) 
12 (4) 
14 (8) 
19 (77) 
9 (36) 
1 
2 
5-7 
2 
2 
1 
7 
2 
3 
3 
2 
3 
Control 
Lipid-modifying 
Control 
Lipid-modifying 
Control 
Lipid-modifying 
Nitrates 
Nifedipine 
Propranolol 
Control 
Lipid-modifying 
Control 
Lifestyle change 
Lipid-modifying 
Lipid-modifying 
Observational 
Observational 
Observational 
Observationa 
3 Observational 
3 Observational 
3 Observational 
3 Observational 
3 Lipid-modifying (femoral) 
1 Lipid-modifyrng (femoral) 
evaluation of a new treatment because they may 
provide essential insights into the mechanisms 
involved. In addition to angiographic benefit, an 
intervention should also be safe and show clini- 
cal benefit, even if a relation clearly exists 
between the substitute end point and the clini- 
cal end point,s6 as in the case of coronary 
atherosclerosis and angina pectoris, acute myo- 
cardial infarction, and sudden cardiac death.*’ 
Therefore, angiographic trials should be comple- 
mented by studies that are large enough to show 
clinical benefit and can provide sufficient infor- 
mation about the incidence of side effects. 
Limitations of Coronary Angiography 
Coronary angiography provides shadow im- 
ages of coronary lumina formed by roentgen ray 
absorption of contrast medium dissolved in 
b1ood.s” Therefore, no direct information about 
the arterial wall is obtained. Focal atheroscle- 
rotic disease, forming a raised plaque, can be 
recognized from a narrowing of the contrast 
column. Diffuse atherosclerotic disease results 
in a continuous narrowing of the lumen that 
cannot directly be identified and can only be 
suspected in the case of an unusual small 
epicardial vessel. Both clinical investigationsyO 
and autopsy studiesgl in patients who died from 
a cardiac cause have shown that diffuse athero- 
sclerosis is a dominant factor as regards athero- 
sclerotic involvement of the coronary arteries,“’ 
and that up to 90% of the coronary segments 
are narrowed more than 25% in the cross- 
sectional area. Early stages of coronary athero- 
sclerosis are accompanied by a compensatory 
enlargement of the coronary vesseP9” or even 
an overcompensation. Only when 40% of the 
internal elastic lamina area is occupied by an 
atherosclerotic lesion is the lumen decreased.“-’ 
This indicates the inability of coronary angiogra- 
phy to detect the early stages of atherosclerosis. 
Thus, it can be argued that the angiographic 
definition of a new lesion97,“x does not exist but 
is in fact an existing atherosclerotic plaque that 
begins to encroach on the vessel lumen. The 
assumptions about the shape of the vessel might 
not be valid. The shape of the lumen at the side 
of an atherosclerotic plaque cannot only be 
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circular but also elliptical or D-shaped,?” which 
can cause underestimation or overestimation of 
the stenosis. 
The visual interpretation of coronary angio- 
grams is hampered by a large interobserver and 
intraobserver variability.99-103 Quantitative coro- 
nary angiography also has sources of erro9“ but 
has a much better reproducibility and is able to 
give absolute measures of coronary artery dimen- 
sions.‘” In conclusion, coronary angiography has 
specific limitations both in the assessment of 
early atherosclerotic lesions and diffuse athero- 
sclerosis. 
End Points 
between angiograms,36,7x severe lesions .36,7X. Ill+ilk 
irregular ulcerating plaquesz8 large extent of 
CAD,78J0s the presence of collaterals,‘H smok- 
ing,28.31 and an abnormal response to ergono- 
vine”” were associated with atherosclerotic dis- 
ease progression including the occurrence of 
total occlusion. However, progression was also 
less often observed in angiographic normal 
segments or in lesions <50%. These studies 
suggested that the progression of CAD does not 
occur in a linear fashion and is unpredict- 
able.“,“” Important drawbacks in these observa- 
tional studies are the retrospective nature and 
the fact that repeat angiograms were performed 
for clinical reasons. 
Relative measures, such as percentage diame- 
ter stenosis or percentage area stenosis, are 
dependent of the determination of the normal 
vessel contour. This normal vessel border at the 
site of a stenosis is unknown and therefore is 
traced manually” or constructed by computer 
systems yielding an interpolated reference diam- 
eter.76 Progression of diffuse atherosclerosis at 
both sides of a stenosis, resulting in a smaller 
reference diameter, may cause pseudoregres- 
sion of the lesion itself (Fig 4). In contrast, the 
mean diameter (mm) of a coronary segment and 
minimal diameter (mm) of an atherosclerotic 
lesion are direct measurements independent of 
the assumed reference diameter. Coronary anat- 
omy should be evaluated by quantitative coro- 
nary angiography and should provide absolute 
measures of both stenosed and nonstenosed 
segments of the coronary artery, thereby assess- 
ing both focal and diffuse atherosclerosis as de 
Feyterz4 recently proposed (Table 12). 
Retrospective studies in patients with unsta- 
ble angina pectorislOR~lOy and in survivors of 
acute myocardial infarction’“‘-“” have shown 
these events were caused both by progression of 
disease in coronary segments that were already 
severely stenosed and also in coronary segments 
that contained a nonsevere lesion or were angi- 
ographically normal at previous angiography. 
One study Ilo showed that the preexisting lesions 
associated with Q wave infarction appeared to 
be less severe than those with non-Q wave 
infarction. An explanation might be that a 
chronic severe lesion possibly protects the myo- 
cardium during acute occlusion and subsequent 
sudden ischemia by the already induced collat- 
erals.“5~‘1h An important bias that invalidates 
these trials is that no information is available on 
patients who have died or who did not need to 
undergo coronary angiography after an acute 
myocardial infarction. 
Coronary Angiography, Progression of Coronary 
Atherosclerosis, and Clinical Events 
Observational studies with repeated coronary 
angiography have shown that a long time period 
Endothelial dysfunction and disruption plays 
an important role in the development of acute 
ischemic events.‘i7 Angiography does not di- 
rectly assess endothelial function. Some studies 
reported abnormal vasomotor reactivity of angi- 
ographically diseased and nondiseased coro- 
112 mm 
3mm 
2mm 2mm 
Fig 4. Diagram of progression 
112 mm of diffuse coronary atherosclaro- 
sis in a segment with preexisting 
MEASUREMENTS: 
DS”o 
Mean width segm. (mm) 
Min. lum. diam. (mm) 
Plaque area (mm ) 
25 
3.75 
3.0 
2.0 
17 
2.9 
2.5 
1.0 
stenosis. Relative measurements 
(OS% relative percent diameter 
stenosis) suggest regression of 
severity of lesion, whereas, in 
reality, absolute measurements 
(mean width, minimal luminal di- 
ameter, and plaque area) show 
progression of coronary CAD. 
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Table 12. Significance of Measurements Used to Assess Progression or Regression of Coronary Atherosclerosis 
Diffuse FOCE3l Diffuse and Focal 
Atherosclerosis Atherosclerosis Atherosclerosis 
Coronary segment score 
Mean width per vessel segment (mm) ++ + ++ 
Coronary lesion score 
Absolute measurements + ++ + 
Minimal luminal diameter (mm) 
Minimal cross-sectional area (mmz) + ++ + 
Plaque area (mm*) - +t + 
Relative stenosis measurements 
Relative percent diameter stenosis (%) - + + 
Area stenosis (%) - + k 
Functional stenosis measurements 
Delta P (mm HG) - f + 
-~ 
NOTE. -, not relevant; k, more or less relevant; f, relevant; ++, highly relevant. 
nary segments after the administration of acetyl- 
choline,1t8J19 serotonin,lzOJzl and papaverine.l12 
Endothelial dysfunction in angiographically nor- 
ma1 segments may be caused by diffuse athero- 
sclerosis or extraluminal atherosclerotic lesions. 
Plaque fissuring and its sequelae can therefore 
occur in these angiographically normal seg- 
ments (Fig 5). Clinical benefit from lipid- 
modifying treatments may not only be mediated 
through less progression of severe plaques but 
also by stabilization of less severe lesions and 
improvement of endothelial function as was 
shown in animal experiments.“’ 
The Angiographic Methods Used in the Selected 
Trials 
The methods used for the assessment of the 
coronary anatomy in the selected trials were 
diverse (Table 2). The first investigators, being 
pioneers in the field, all visually assessed the 
diameter 
stenosis 
100% 
80% 
60% 
40% 
20% 
40% 0% 
/‘IV: impaired flow 
,,” intraluminal 
plaque 
I / III: anglographically detectable 
./ 
: endothellal dysfunction 
0% ~ 
,/II: 
plaque I: not diseased 
area time -> 
extraluminal 
plaque 
Fig 5. Illustration of the possible natural history of atherosclerotic plaque progression, plaque fissure, thrombosis, and clinical 
coronary events. Phase I: no atherosclerotic plaque is present, the endothelial function is intact, no thrombosis will occur. Phase II: 
an atherosclerotic plaque is present, the internal elastic lamina is for ~40% occupied by atheroma and does not encroach on the 
lumen, the lesion is not angiographically detectable, plaque fissure, thrombosis and occlusion causing unstable angina pectoris or 
acute myocardial infarction may occur. Phase III: the internal lamina elastica is 240% occupied by an atheroma and encroaches on 
the lumen, the lesion is angiographically detectable. Phase IV: a severe narrowing of the lumen is present, plaque fissure, 
thrombosis, occlusion causing unstable angina pectoris or acute myocardial infarction may occur. A severe lesion might induce 
collaterals that could protect the myocard against sudden ischemia and prevents clinically overt coronary events. 
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angiograms and used relative percent diameter 
stenosis as the main criteria. But as knowledge 
about the assessment of coronary anatomy 
evolved, investigators began to use quantitative 
techniques; recent trials all use this technique. 
Most assessments were based on the relative 
percent diameter stenosis of coronary lesions. 
The criteria used to define clinically significant 
lesions on patient status change were varied 
(Table 2). A criterion for lesion change applied 
by several trials was 2 10% in percent relative 
diameter stenosis. The most recent trial, the 
STARS study, used mean and minimal vessel 
diameter as the primary angiographic end points. 
The diversity of angiographic methods applied 
illustrates that no consensus as yet exists how to 
assess coronary artery changes in absolute terms, 
which hampers the comparison and overview of 
the trials. 
Effect of Lipid-Modifying Therapy on Coronav 
Anatomy 
The common object in these trials was to 
improve the lipid profile. They all used different 
therapies to achieve such a shift, ranging from 
diet and one lipid-modifying drug through mul- 
titherapy to partial ileal bypass surgery. All 
these treatment regimes results in substantial 
reductions in total cholesterol, LDL choles- 
terol, and triglycerides up to 36%, 45%, and 
29%, respectively; although in some instances 
an elevation of triglycerides occurred (Table 2). 
Also large elevations of HDL were observed, 
whereas in the POSCH and the STARS studies 
HDL remained unchanged. It can be concluded 
NHLBI II CLAS POSCH FATS 
100% - 
80% - 
ao%,l 
r 
P LM P LM P LM P LM 
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that the treatment regimes used were very 
effective in improving the lipid profile. Pooling 
of the selected trials presents evidence that 
extensive beneficial changes in the lipid-profile 
results in retardation, arrest of progression, or 
regression of CAD. (Fig 6). In the 1,240 patients 
(666, lipid-modified group; 574, control group) 
a substantial reduction in the number of pa- 
tients who showed progression of CAD was 
noted (184 [28%] in the lipid-modified group 
versus 261 [46%] in the control group). Further- 
more, a less substantial increase in the number 
of patients who showed regression of CAD (107 
[16%] in the lipid-modified group versus 40 
[7%] in the control group) was found. 
The absolute changes in coronary artery ste- 
nosis measured were small and therefore will 
have little functional importance. On the other 
hand, when these changes are extrapolated to a 
longer period, an important functional improve- 
ment might occur. POSCH is the only trial that 
presents data on the long-term effects of lipid- 
lowering. Figure 7 shows that the angiographic 
benefit is present after 3 years and remains 
constant while the absolute incidence of progres- 
sion increases over the years with a progression 
rate of more than 8.5% in the control group and 
55% in the operated group after 10 years. The 
effect on regression increased up to 7 years with 
6.3% in the control group and 14.4% in the 
surgery group. 
Data from histological-and physical bio- 
chemical studies’?l and epidemiological stud- 
ies’8 suggest that regression of CAD is mediated 
by HDL. The STARS study, however, in which 
Kane STARS 
P LM 
Fig 6. Changes in CAD in five 
coronary atherosclerosis trial 
with a lipid-modifying treatment. 
P, placebo; LM, lipid-modifying 
treatment; 8. progression; Cl, 
P LM stable or mixed; n . regression. 
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8094 
60% 
Fig 7. Changes over time in the 40% 
POSCH trial. Coronary angiogra- 
phy was performed at 3,5,7. and 
10 years after randomization. Num- 
bers indicate the numbers of pa- 20% 
tients at each time interval for each 
treatment group. C, control group; 
S, partial ileal bypass surgery; 8, 
progression; 0, stable or mixed; 533 363 
n , regression. c s 
3 years 
no change in HDL was seen, shows that regres- 
sion of CAD can occur in the absence of HDL 
elevation. 
Effect of Diet and Lifestyle Changes on Coronary 
Anatomy 
The Lifestyle Heart Study and the STARS 
trial provide data on the effect of lifestyle 
changes and diet on CAD. In the former a 
combination of diet, daily exercise, and stress 
management techniques resulted in a substan- 
tial improvement of blood lipids, a reduction of 
angina1 complaints, and a 60% reduction in 
progression of CAD and a twofold increase of 
regression. In the latter a lipid lowering-diet 
only was responsible for the largest angio- 
graphic benefit: change in mean coronary artery 
diameter 0.03 mm versus 0.20 mm in the control 
group. No difference was seen between the 2 
intervention groups in categorical progression 
or regression of CAD and clinical events. The 
CLAS investigators studied the relation be- 
tween diet and the occurrence of new lesions in 
their placebo group. 125 Progression of CAD was 
associated with a higher consumption of total- 
and polyunsaturated fat. Patients who compen- 
sated for the lower saturated fat intake, pre- 
scribed by the diet, by increasing protein intake 
instead of consuming more polyunsaturated fat, 
had the lowest risk of developing new atheroscle- 
rotic lesions. In the uncontrolled Leiden Inter- 
vention Tria1,38 a vegetarian diet was associated 
with a reduction in body-weight, systolic blood 
pressure, and total cholesterol. Progression of 
5 years 7 years 
301 333 174 187 80 95 
c s c s c s 
CAD was stopped in 18 of 39 patients and was 
related to the total cholesterol/HDL ratio. 
The Coronary Atherosclerosis Trials with 
Calcium Channel Blockade 
The two studies by Lichtlen et al. and Waters 
et al. had similar study designs. Both trials 
recruited patients with mild to moderate CAD, 
treated with either placebo or a dihydropyridine 
calcium antagonist. The analyses of the coro- 
nary angiograms were performed with the same 
quantitative system (UUU’~). The pooled re- 
sults are therefore a precise estimate of the 
effect of these agents on CAD. Both studies 
failed to demonstrate an overall effect of cal- 
cium channel blockade on progression or regres- 
sion of CAD. On a segmental level little effect 
was found on angiographically new- or minimal 
lesions. INTACT showed a reduction in the 
occurrence of angiographically new lesions. In a 
secondary analysis, Waters et al. found less 
progression of lesions less then 20% diameter 
stenosis. In the trial by Waters this effect was 
related to a lowering of blood pressure. The 
number of cardiac events and deaths were 
larger in the calcium antagonist groups. Thus, 
although animal studies have shown antiathero- 
sclerotic properties of several calcium antago- 
nists,” no clear benefit of these agents on 
overall progression of CAD is found in men. 
The Femoral Atherosclerosis Trials 
The epidemiology of femoral atherosclerosis 
may be different from that of coronary athero- 
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sclerosis. The most important risk factors re- 
ported are age, pack-years of cigarettes, systolic 
blood pressure, plasma glucose and obesity. 
However, the relation between blood lipids and 
femoral atherosclerosis is inconsistent. Studies 
showing both an association126-12y or a lack of 
association’“O have been reported. Results from 
pathologic studies suggest the structure of the 
femoral atherosclerotic plaque may be different 
from coronary lesions being predominantly fibro- 
proliferative and containing little lipid.‘“’ 
CONCLUSION 
The 2 trials testing calcium channel blockade 
showed no beneficial effect on preexisting ath- 
erosclerotic plaques, but this treatment may 
have an effect on the development of angio- 
graphically new lesions. The increased number 
of clinical events in the calcium antagonist 
groups emphasizes that safety of an interven- 
tion should be taken into account. 
Until now only 3 controlled trials, of which 2 
were randomized, with a total of 220 patients 
have been carried out. Different types of pa- 
tients were recruited in these trials: patients 
with symptomatic femoral atherosclerosis, with 
hyperlipoproteinemia, and patients post-CABG. 
All trials showed that a lipid-modifying treat- 
ment resulted in a reduction of progression of 
femoral atherosclerosis and an increase of re- 
gression. 
Generalization of Results 
We selected 5 trials testing the lipid hypothe- 
sis on coronary atherosclerosis. The kinds of 
patients enrolled were different, the lipid- 
modifying treatments varied, different methods 
of coronary analysis were used and different 
coronary endpoints were employed. AI1 were 
secondary prevention trials in patients with 
elevated blood lipids, with proven CAD, who 
underwent coronary bypass surgery or who had 
previously suffered from an acute myocardial 
infarction. The treatments ranged from mono- 
therapy, combination therapy to accomplish a 
minimal level of lipid-lowering, to abdominal 
surgery, and extremely demanding lifestyle 
changes. This may have consequences for large 
scale use since patient compliance will be diffi- 
cult to maintain and treatments will be expen- 
sive. 
The results of several lipid-modifying trials 
with different designs were pooled. This quanti- 
tative overview will, therefore, be hampered by 
the heterogeneity of these studies. Intensive 
lipid-modifying treatment in patients with high 
levels of plasma cholesterol with moderate to 
severe CAD and at relatively high risk for 
cardiac events, resulted in large reductions in 
total cholesterol and elevations of HDL. This 
was associated with slowing or arrest of progres- 
sion of CAD in a substantial number of patients 
(27% versus 46%) and an increase in the 
incidence of regression of CAD in relatively few 
patients (17% versus 7%~). However. the in- 
duced angiographic changes are relatively small 
and exert only minimal effects on the functional 
significance of lesions. One should however 
bear in mind that, apart from the POSCH trial, 
the interventions were maintained only 1 to 3 
years. These effects may be cumulative and 
functional more impressive if extended for a 
much larger time period. However, these trial 
also show that, although patients are submitted 
to extensive treatment regimes, progression does 
occur in 14% to 39% after 3 years and 55% after 
10 years indicating that lipid-modifying therapy 
may not be effective in a large number of 
patients. The 3 femoral atherosclerosis trials 
showed, although epidemiological data give no 
clear picture of the risk factors involved, that 
lipid-modifying treatment may also be benefi- 
cial for femoral atherosclerosis. 
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